{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:09:00Z","timestamp":1793869740023,"version":"4.6.1"},"reference-count":88,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor (CAR) T-cell therapy research is critical for understanding the impact of this novel approach from a unique patient standpoint. We performed a scoping review to map the available literature on the use of PRO measures in CAR T-cell therapy studies of patients with hematologic malignancies published between January 2015 and July 2022. Fourteen studies were identified, of which 7 (50%) were investigational early-phase trials, 6 (42.9%) were observational studies, and 1 (7.1%) was a pilot study. The EQ-5D and the PROMIS-29 were the 2 most frequently used PRO measures, being included in 6 (42.9%) and 5 (35.7%) studies, respectively. Despite differences in study designs, there seems to be evidence of improvements over time since CAR T-cell infusion in important domains such as physical functioning and fatigue, at least in patients who respond to therapy. Overall, the studies identified in our review have shown the added value of PRO assessment in CAR T-cell therapy research by providing novel information that complements the knowledge on safety and efficacy. However, there are several questions which remain to be answered in future research. For example, limited evidence exists regarding patient experience during important phases of the disease trajectory as only 4 (28.6%) and 5 (35.7%) studies provided information on PROs during the first 2 weeks from CAR T-cell infusion and after the first year, respectively. Time is ripe for a more systematic implementation of high-quality PRO assessment in future clinical trials and in real-life settings of patients treated with CAR T-cell therapy.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000802","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:01:28Z","timestamp":1674493288000},"page":"e802","source":"Crossref","is-referenced-by-count":35,"title":["Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review"],"prefix":"10.1002","volume":"6","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry II, Medical University of Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Hematology, University and CHU of Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[{"name":"Palliative Care & Rehabilitation Medicine, UT M. D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cellular Therapy, Medical Clinic and Policlinic I, Leipzig University Hospital, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"R1-20231116","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer.","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"R2-20231116","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20231116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-20231116","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"R5-20231116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R6-20231116","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R7-20231116","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"R8-20231116","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"R9-20231116","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20231116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R11-20231116","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R12-20231116","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/bloodadvances.2020003848","article-title":"Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.","volume":"5","author":"Neelapu","year":"2021","journal-title":"Blood Adv"},{"key":"R13-20231116","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R14-20231116","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20231116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"R16-20231116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma.","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20231116","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study.","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R20-20231116","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"R21-20231116","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-20231116","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"R23-20231116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R24-20231116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20231116","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"R26-20231116","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R27-20231116","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"R28-20231116","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"key":"R29-20231116","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas.","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"R30-20231116","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"R31-20231116","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies.","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"R32-20231116","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2019-0646","article-title":"EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-cell lymphoma.","volume":"25","author":"Papadouli","year":"2020","journal-title":"Oncologist"},{"key":"R33-20231116","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41409-020-01029-4","article-title":"Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R34-20231116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells.","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R35-20231116","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies.","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R36-20231116","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections.","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R37-20231116","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.21.00195","article-title":"Understanding treatment tolerability in older adults with cancer.","volume":"39","author":"Flannery","year":"2021","journal-title":"J Clin Oncol"},{"key":"R38-20231116","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"key":"R39-20231116","doi-asserted-by":"crossref","first-page":"390.e391","DOI":"10.1016\/j.jtct.2021.01.003","article-title":"Patient-reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor T cell therapy: a systematic review.","volume":"27","author":"Kamal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R41-20231116","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation.","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"R42-20231116","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd.2017.84","article-title":"CAR T therapies drive into new terrain.","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R44-20231116","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s43441-020-00184-6","article-title":"Use of patient-reported outcomes to understand & measure the patient experience of novel cell and gene therapies.","volume":"54","author":"Lasiter","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"R45-20231116","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"R46-20231116","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy.","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R47-20231116","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma.","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"R48-20231116","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel.","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"key":"R49-20231116","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma.","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"key":"R50-20231116","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T-cells: a prospective cohort study.","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"key":"R51-20231116","doi-asserted-by":"crossref","first-page":"930.e931","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies.","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R52-20231116","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"key":"R53-20231116","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients\u2014a matched control multicenter cohort study.","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"R54-20231116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s43856-022-00116-5","article-title":"Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.","volume":"2","author":"Knight","year":"2022","journal-title":"Commun Med"},{"key":"R55-20231116","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.3390\/cancers14112742","article-title":"Longitudinal collection of patient-reported outcomes and activity data during CAR-T therapy: feasibility, acceptability, and data visualization.","volume":"14","author":"Oswald","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R56-20231116","doi-asserted-by":"crossref","first-page":"401.e401","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients\u2019 perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma.","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R57-20231116","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R58-20231116","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"R59-20231116","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.","author":"Elsawy","year":"2022","journal-title":"Blood"},{"key":"R60-20231116","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant.","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R61-20231116","doi-asserted-by":"crossref","first-page":"100304","DOI":"10.1016\/j.jcpo.2021.100304","article-title":"Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.","volume":"30","author":"Raymakers","year":"2021","journal-title":"J Cancer Policy"},{"key":"R62-20231116","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","article-title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.","volume":"12","author":"Pratz","year":"2022","journal-title":"Blood Cancer J"},{"key":"R63-20231116","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab.","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"R64-20231116","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","article-title":"Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.","volume":"32","author":"Efficace","year":"2014","journal-title":"J Clin Oncol"},{"key":"R65-20231116","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia.","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"R66-20231116","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase I clinical trials.","volume":"113","author":"Veitch","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R67-20231116","doi-asserted-by":"crossref","first-page":"pkaa067","DOI":"10.1093\/jncics\/pkaa067","article-title":"Using patient-reported outcomes to describe the patient experience on phase I clinical trials.","volume":"4","author":"Sedhom","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"R68-20231116","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"R71-20231116","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1002\/cam4.4307","article-title":"Trends in patient-reported outcome use in early phase dose-finding oncology trials\u2014an analysis of ClinicalTrials.gov.","volume":"10","author":"Lai-Kwon","year":"2021","journal-title":"Cancer Med"},{"key":"R72-20231116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1114649","article-title":"Toward patient-centered drug development in oncology.","volume":"369","author":"Basch","year":"2013","journal-title":"N Engl J Med"},{"key":"R73-20231116","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"R74-20231116","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/bjh.16532","article-title":"Importance of quality of life in early phase clinical trials: a case study of selinexor in multiple myeloma.","volume":"189","author":"Chakraborty","year":"2020","journal-title":"Br J Haematol"},{"key":"R75-20231116","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities.","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R76-20231116","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial.","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"R77-20231116","doi-asserted-by":"crossref","first-page":"e25271","DOI":"10.2196\/25271","article-title":"The GIMEMA-ALLIANCE digital health platform for patients with hematologic malignancies in the COVID-19 pandemic and postpandemic era: protocol for a multicenter, prospective, observational study.","volume":"10","author":"Efficace","year":"2021","journal-title":"JMIR Res Protoc"},{"issue":"Suppl 1","key":"R78-20231116","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2021-149103","article-title":"Pilot implementation of remote patient monitoring program for outpatient management of CAR-T cell therapy.","volume":"138","author":"Paludo","year":"2021","journal-title":"Blood"},{"key":"R79-20231116","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2022.1044","article-title":"Assessment of hospitalizations and emergency department visits after chimeric antigen receptor T-cell therapy among commercially insured patients.","volume":"8","author":"Kenzik","year":"2022","journal-title":"JAMA Oncol"},{"key":"R80-20231116","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41746-022-00663-0","article-title":"A framework for digital health equity.","volume":"5","author":"Richardson","year":"2022","journal-title":"NPJ Digit Med"},{"key":"R81-20231116","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline.","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"R82-20231116","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2021-146032","article-title":"Worsening financial toxicity among patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: a mixed methods longitudinal study.","volume":"138","author":"Cusatis","year":"2021","journal-title":"Blood"},{"key":"R83-20231116","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the comprehensive score for financial toxicity (COST).","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"key":"R84-20231116","doi-asserted-by":"crossref","first-page":"e049128","DOI":"10.1136\/bmjopen-2021-049128","article-title":"Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system.","volume":"11","author":"Riva","year":"2021","journal-title":"BMJ Open"},{"key":"R85-20231116","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JOP.19.00200","article-title":"Assessing financial toxicity in patients with cancer: moving away from a one-size-fits-all approach.","volume":"15","author":"Perrone","year":"2019","journal-title":"J Oncol Pract"},{"key":"R86-20231116","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2015.63.2232","article-title":"Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer.","volume":"34","author":"Lathan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R87-20231116","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer.","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"R88-20231116","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdw433","article-title":"The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy.","volume":"27","author":"Perrone","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"R89-20231116","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2021-145746","article-title":"Do PROs tell the whole story? Differential outcomes based on patient-reported outcomes (PROs) versus performance-based metrics (PBM) on cognition for patients receiving chimeric antigen receptor (CAR)-T cell therapy.","volume":"138","author":"Tan","year":"2021","journal-title":"Blood"},{"key":"R90-20231116","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/pon.5674","article-title":"Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy.","volume":"30","author":"Barata","year":"2021","journal-title":"Psychooncology"},{"key":"R91-20231116","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","article-title":"Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.","volume":"29","author":"Sheykhhasan","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"R92-20231116","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/hematology.2020000100","article-title":"Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas.","volume":"2020","author":"Odejide","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R93-20231116","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/cancers14030478","article-title":"Early palliative care in acute myeloid leukemia.","volume":"14","author":"Potenza","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R94-20231116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjh.18286","article-title":"Early integration of palliative care for patients with haematological malignancies.","volume":"199","author":"Shaulov","year":"2022","journal-title":"Br J Haematol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:05:37Z","timestamp":1702922737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":88,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000802","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}